PURPOSE: To analyze the results of daily high-dose-rate brachytherapy (HDRBT) on local control and toxicity in the postoperative treatment of endometrial carcinoma (EC). MATERIALS AND METHODS: From January 2007 to September 2010, 112 patients were treated with HDRBT after surgery for EC. FIGO staging: 24-IA, 48-IB, 14-II, 12-IIIA, 2-IIIB, 8-IIIC1 and 4-IIIC2. Pathology 99/112 endometrioid and 23/112 other types. Radiotherapy patients were divided into two groups-Group 1 (70/112) consists of external beam irradiation (EBI) plus HDRBT (2 fractions of 5-6 Gy) and Group 2 (42/112) consists of HDRBT alone (4 fractions of 5-6 Gy). Toxicity evaluation RTOG scores for bladder and rectum, and the objective criteria of LENT-SOMA for vagina. Statistics bivariate analysis of Chi-square and Fisher exact tests. RESULTS: With a mean follow-up of 29.52 months (range 9.60-53.57) no patient developed vaginal-cuff relapse. In Group 1 early toxicity appeared in 9 % in rectum, 8.5 % in bladder (G1-G2) and 1.4 % in vagina (G1); late toxicity was present in 8.5 % in rectum (all G1-G2 but 1 G3) and in 25 % in vagina (all G1-G2 but one G4). In Group 2, 9.4 % developed G1-G2 bladder and 6.9 % acute vagina (G1-G2) toxicity. Only 2.3 % had a G1 rectal score and 6.9 % had G1-G2 as vaginal scores for late problems. CONCLUSIONS: (1) Daily HDRBT using two fractions of 5-6 Gy after EBI and four fractions of 5-6 Gy as exclusive treatment was a safe regime. (2) Group 1 showed a higher incidence of late vaginal toxicity.
PURPOSE: To analyze the results of daily high-dose-rate brachytherapy (HDRBT) on local control and toxicity in the postoperative treatment of endometrial carcinoma (EC). MATERIALS AND METHODS: From January 2007 to September 2010, 112 patients were treated with HDRBT after surgery for EC. FIGO staging: 24-IA, 48-IB, 14-II, 12-IIIA, 2-IIIB, 8-IIIC1 and 4-IIIC2. Pathology 99/112 endometrioid and 23/112 other types. Radiotherapy patients were divided into two groups-Group 1 (70/112) consists of external beam irradiation (EBI) plus HDRBT (2 fractions of 5-6 Gy) and Group 2 (42/112) consists of HDRBT alone (4 fractions of 5-6 Gy). Toxicity evaluation RTOG scores for bladder and rectum, and the objective criteria of LENT-SOMA for vagina. Statistics bivariate analysis of Chi-square and Fisher exact tests. RESULTS: With a mean follow-up of 29.52 months (range 9.60-53.57) no patient developed vaginal-cuff relapse. In Group 1 early toxicity appeared in 9 % in rectum, 8.5 % in bladder (G1-G2) and 1.4 % in vagina (G1); late toxicity was present in 8.5 % in rectum (all G1-G2 but 1 G3) and in 25 % in vagina (all G1-G2 but one G4). In Group 2, 9.4 % developed G1-G2 bladder and 6.9 % acute vagina (G1-G2) toxicity. Only 2.3 % had a G1 rectal score and 6.9 % had G1-G2 as vaginal scores for late problems. CONCLUSIONS: (1) Daily HDRBT using two fractions of 5-6 Gy after EBI and four fractions of 5-6 Gy as exclusive treatment was a safe regime. (2) Group 1 showed a higher incidence of late vaginal toxicity.
Authors: William Small; Sushil Beriwal; D Jeffrey Demanes; Kathryn E Dusenbery; Patricia Eifel; Beth Erickson; Ellen Jones; Jason J Rownd; Jennifer F De Los Santos; Akila N Viswanathan; David Gaffney Journal: Brachytherapy Date: 2012 Jan-Feb Impact factor: 2.362
Authors: Lua Eiriksson; Julie Cuartero; Helen Steed; Robert Pearcey; Valerie Capstick; Alexandra Schepansky; Wylam Faught; George Dundas Journal: Int J Gynecol Cancer Date: 2010-11 Impact factor: 3.437
Authors: J L Guinot; J Pérez-Calatayud; J M Azcoaga; I Herruzo; C Bodineau; A Rovirosa; V Crispín; P Galán; E González-Patiño; J Pérez-Regadera; A Polo Journal: Clin Transl Oncol Date: 2012-04 Impact factor: 3.405
Authors: Angeles Rovirosa; Carlos Ascaso; Alberto Sánchez-Reyes; Antonio Herreros; Rosa Abellana; Jaume Pahisa; Jose Antonio Lejarcegui; Albert Biete Journal: Int J Radiat Oncol Biol Phys Date: 2010-08-26 Impact factor: 7.038
Authors: S Sabater; Ma M Sevillano; I Andres; R Berenguer; S Machin-Hamalainen; K Müller; M Arenas Journal: Strahlenther Onkol Date: 2013-09-04 Impact factor: 3.621
Authors: I Valduvieco; Á Rovirosa; A Herreros; I Romera; I Ríos; C Ascaso; A Sánchez-Reyes; M Arenas; J Pahisa; A Biete Journal: Clin Transl Oncol Date: 2012-12-21 Impact factor: 3.405
Authors: I Ríos; A Rovirosa; C Ascaso; I Valduvieco; A Herreros; L Castilla; S Sabater; K Holub; J Pahisa; A Biete; M Arenas Journal: Clin Transl Oncol Date: 2015-12-11 Impact factor: 3.405
Authors: Amelia Barcellini; Mattia Dominoni; Francesca Dal Mas; Helena Biancuzzi; Sara Carla Venturini; Barbara Gardella; Ester Orlandi; Kari Bø Journal: Front Med (Lausanne) Date: 2022-02-03
Authors: María Del Valle Aguilera; Ángeles Rovirosa; Carlos Ascaso; Antonio Herreros; Joan Sánchez; Julia Garcia-Migue; Stephanía Cortes; Eduardo Agusti; Cristina Camacho; Yaowen Zhang; Yan Li; Sebastià Sabater; Aureli Torne; Meritxell Arenas Journal: J Contemp Brachytherapy Date: 2018-02-28